ERBB2 and breast cancer: Masuda et al.12 showed the benefit of capecitabine as an adjuvant treatment option for HER2-negative breast cancer patients with residual invasive disease after NCT and currently, the drug is approved for use in TNBC patients not achieving pCR in the U.S..